UICC signs MoU on behalf of the ATOM Coalition to improve access to essential cancer medicines in Mongolia

The Memorandum of Understanding, reached with the support of National Cancer Council of Mongolia, bolsters the national strategy to enhance the availability of quality-assured oncology medicines.

Dr Tsetsegsaikhan Batmunkh (second from right), CEO of the National Cancer Council Mongolia with Dr Dan Milner (far left), Executive Director of the ATOM Coalition, with Sumi Krishnamurthy (far right), consultant with the ATOM Coalition and staff from the National Cancer Council Mongolia.

UICC is delighted to announce that it has signed a Memorandum of Understanding (MoU) with the Ministry of Health in Mongolia on behalf of the Access To Oncology Medicines (ATOM) Coalition, an initiative launched by UICC with some 40 partners across the private and civil society sectors, has signed

The MoU represents an important step towards improving access to and the availability of quality-assured cancer medicines within the country.

"The invaluable support of UICC member, the National Cancer Council of Mongolia, alongside other key national stakeholders such as the Medical Devices Regulatory Agency and the Pharmaceutical Association, played a crucial role in reaching this significant milestone."
– Dan Milner, Executive Director of the ATOM Coalition

The ATOM Coalition, with the support of UICC and in close collaboration with the Ministry of Health and local partners, is now focused on implementing strategies that will facilitate better access to essential oncology medicines. An immediate priority in this endeavour is the appointment of a country representative to efficiently coordinate the coalition's activities across Mongolia.

Tags National Cancer Council of Mongolia ATOM Coalition Access to Medicines

Last update

Wednesday 06 November 2024

Related content

In a landmark step for equitable cancer care, patients in three low- and middle-income countries (LMICs) are now accessing stringent regulatory authority (SRA)-approved generic nilotinib through the ATOM Coalition’s innovative approach to access and collaboration.

UICC welcomes the addition of new cancer treatments for leukaemia, lung, cervical, and colorectal cancers in the new WHO EML released last week. Continued advocacy and collaboration are essential, however, to ensure equitable access and translate listings into meaningful patient outcomes.